



PREDICTIVE ANALYSIS OF MATERNAL SUBCUTANEOUS FAT THICKNESS FOR THE RISK OF DEVELOPMENT OF GESTATIONAL DIABETES MELLITUS

Aditi Arora¹, Sachin Chakarrvarti DM², Ishita Agrawal³, Premlata Mital^{4*},
Isha Ramneek⁵ and Sakshi Bansal⁶

^{1,3,4,5,6}OB-GY. S.M.S. Medical College, Jaipur
²Hepatopancreato biliary sciences MMC Chennai

ARTICLE INFO

Article History:

Received 15th January, 2022

Received in revised form 7th

February, 2022

Accepted 13th March, 2022

Published online 28th April, 2022

Key words:

Obesity, Gestational diabetes mellitus, body mass index, abdominal subcutaneous fat thickness, ultrasonography

ABSTRACT

Introduction: In recent years the prevalence of gestational diabetes mellitus is remarkably increased. Obesity is the most important risk factor for GDM. Abdominal obesity is associated with insulin resistance and metabolic syndrome. Maternal abdominal subcutaneous fat thickness is highly correlated with obesity and can be measured by ultrasonography. This study was done to find correlation between maternal ASCFT and development of GDM and to find a cut-off value of ASCFT for prediction of risk of developing GDM.

Material and method: This was a prospective observational study. 200 women included in the study were classified as normal (n=181) and with GDM (n=19) on the basis of DIPSI. Abdominal subcutaneous fat thickness was measured by ultrasonography. Data were evaluated statistically.

Results: Mean age of the women who developed GDM (27.47 ± 2.14 years) was significantly more. Receiver-operating characteristic curve analysis showed ASCFT above 15.2 mm predicted GDM with 100% sensitivity and 91.78% specificity and the risk of developing GDM was significantly high [odd ratio-117 (95% CI 14.9262-917.1130, p <0.0001)].

Conclusion: Measurement of abdominal subcutaneous fat thickness by ultrasonography at 16 -18 weeks may help to identify women at risk of developing GDM at 24-28 weeks.

Copyright©2022 Aditi Arora et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Gestational diabetes mellitus (GDM), is the most common metabolic disorder of pregnancy and is defined as any degree of dysglycaemia that occurs for the first time or is first detected during pregnancy, irrespective of treatment with diet or insulin.¹ Recent studies have shown that the risk of developing type 2 diabetes mellitus and metabolic syndrome with the advanced age is increased in patients with a history of GDM.² Metabolic syndrome is correlated with insulin resistance, abdominal obesity, hypertension, and atherogenic dyslipidemia. Abdominal obesity and insulin resistance are responsible for the central role in the pathogenesis of Metabolic syndrome.³ Abdominal obesity seems to be more strongly linked to metabolic disease compared with body mass index (BMI) and anthropometric measures of abdominal obesity [e.g., waist circumference (WC) and waist-to-hip ratio (WHR)].⁴

With the increasing prevalence of obesity and diabetes mellitus there is parallel increase in prevalence of gestational diabetes.⁵ In Asia, the prevalence of GDM ranges from 0.7 to 51.0%.⁶ In India the prevalence of gestational diabetes varies from 3.8%

in Kashmir,⁷ to as high as 41% in Lucknow.⁸ This vast disparity in prevalence rates may be due to differences in ethnicity,⁹ diagnostic criteria¹⁰, screening strategies¹¹, and population characteristics¹².

We are using diagnostic test for GDM as recommended by Diabetes in Pregnancy Study group of India (DIPSI) where plasma glucose is evaluated after two hours of ingestion of 75 g anhydrous glucose in 250 – 300 ml of water irrespective of meal timings. A 2-hours plasma glucose ≥ 140 mg/dl is taken as GDM.¹³

Women with GDM are at increases risk of pre-eclampsia, eclampsia, infectious disease, and the birth rate of large for gestational age fetuses. There is increased perinatal morbidity due to increased risk of infantile respiratory distress syndrome, metabolic disorders, and hyperbilirubinemia in fetuses.⁵ Women are also at risk of developing diabetes after delivery.¹⁴ The age of a mother, her pre-pregnancy body mass index (BMI), the amount of obesity, family history, and weight gain during pregnancy are major risk factors for GDM, but among these, obesity is the most serious risk factor¹⁵. Various biochemical biomarkers like adiponectin, follistatin-like-3

*Corresponding author: Premlata Mital
OB-GY. S.M.S. Medical College, Jaipur

(FSTL3) and sex hormone-binding globulin (SHBG), have been used for early prediction of GDM.¹⁶One of the most limiting factors in using these tests to predict GDM is cost. Pre-pregnancy BMI is used most frequently to assess the risk of pregnancy complications. One of the drawbacks of using BMI is that it depends on pre-pregnancy weight which a woman may not remember so recently maternal abdominal subcutaneous fat thickness (ASCFT) is used to complement the use of BMI to assess risk for GDM. ASCFT is highly correlated with obesity and can be measured by ultrasonography. Measurement of abdominal subcutaneous fat by ultrasound is an easy, quick, non-invasive and cost-effective method. It also avoids the use of ionizing radiation.¹⁷This study was done to find correlation between maternal ASCFT and development of GDM and to find a cut-off value of ASCFT for prediction of risk of developing GDM.

MATERIAL AND METHODS

This was a hospital based prospective observational study conducted in the Department of Obstetrics and Gynaecology. 200 women with singleton live pregnancy between 16 -18 weeks of gestation and willing to participate in the study were included after obtaining written informed consent. Women with type 1 or type 2 diabetes prior to pregnancy or with a previous history of GDM, hypertension were excluded. Pre-pregnancy BMI was calculated for all women. Ultrasonography was done to assess foetal well-being and rule out congenital malformation. Maternal abdominal subcutaneous thickness was measured from the subcutaneous fat layer to the outer border of the rectus abdominus muscle at the level of the linea alba. Three measurements were taken for subcutaneous thickness for each woman and mean subcutaneous thickness was determined. All women included in the study underwent DIPSI test (2 hours sugar after 75 gm of anhydrous glucose) between 24 to 28 weeks of gestation. GDM was diagnosed when plasma glucose levels were above 140 mg/dl.

All data were entered into MS excel sheet and analyzed. To determine the cut-off value for predicting GDM a receiver operating characteristic (ROC) curve analysis was conducted, with the area under the curve (AUC), sensitivity, and specificity calculated. A logistic regression analysis was done to calculate the odds ratio for the ASCFT-mediated risk of GDM. A p value 0.05 was considered to be statistically significant.

RESULTS

Out of 200 women screened, 19 (9.5%) were screened positive for GDM and 181 (90.5%) were screened negative for GDM. Mean age of the women who developed GDM (27.47 ± 2.14 years) was significantly more than mean age of the women who did not developed GDM (23.81 ± 2.69 years) (p – 0.0000). Mean BMI and ASCFT were significantly more in women who developed GDM (28.42 ± 3.06 kg/m² and 17.75 ± 1.82 mm respectively). (Table 1)

Table 1 Age, BMI and ASCFT differences in women with or without GDM

Variables	Total (n=200)	Control (n=181)	GDM (n=19)	P value
Age (year)	24.17 ± 2.86	23.81 ± 2.69	27.47 ± 2.14	0.0000
BMI (kg/m ²)	22.84 ± 2.93	22.25 ± 2.22	28.42 ± 3.06	0.0000
ASCFT (mm)	12.47 ± 3.13	11.92 ± 2.70	17.75 ± 1.82	<0.001

To find an effective cut-off value for predicting GDM by BMI and ASCFT, a ROC curve analysis was conducted which showed that pre-pregnancy BMI above 25 kg/m² (AUC=0.984) predicted GDM with a sensitivity of 100% and specificity of 93.4% and Youden index of 0.93. ROC curve analysis for ASCFT showed that ASCFT above 15.2 mm (AUC=0.970) predicted GDM with a sensitivity of 100% and specificity of 85.6 and Youden index of 0.86. There was no significant difference in the diagnostic performance of BMI (Kg/m²) and SCFT (mm) in prediction of GDM (DeLong's Test p = 0.157). (Table 2 and Fig 1)

Table 2 Receiver operating characteristic prediction curve analysis of variables

Predictor	AUROC	Sensitivity %	Specificity %	Youden Index	P value
BMI (Kg/m ²)	0.984	100%	93.4%	0.93	<0.001
ASCFT (mm)	0.970	100%	85.6%	0.86	<0.001

AUROC: Area under ROC curve, BMI: body mass index.,ASCFT:abdominal subcutaneous fat thickness



Figure 1 ROC for prediction of GDM by BMI & SCFT

Increased abdominal SCFT was significantly associated with increased risk of developing GDM. Using 15.2 mm cut -off value for ASCFT, the odd ratio of GDM in 200 women screened was 117 (95% CI 14.9262-917.1130, p <0.0001). (Table 3)

Table 3 Association of ASCFT with risk of GDM

ASCFT	GDM		Odd Ratio, 95%CI	P value
	Yes (n=19)	No (n=181)		
<15.2 mm	1	157	117.75(15.022-922.956)	<0.0001
≥15.2 mm	18	24		

DISCUSSION

Depending on population sample and diagnostic criteria used, prevalence of GDM ranges from 1 to 20 per cent¹⁸ The incidence of GDM is increasing due to increase in maternal age and obesity among mothers with increase in the GDM related complications.¹⁷ Therefore there is a need to predict the risk of GDM at an early gestational age so that appropriate measures can be taken to prevent GDM. This study was done to measure abdominal subcutaneous fat thickness by ultrasonography at 16 to 18 weeks and to use it to predict GDM at 24-28 weeks.

In our study, out of 200 women screened for GDM 9.5% women were found to be positive. The prevalence of GDM in our study was lower than prevalence observed by Kansu-Celik H *et al* (20%)² and Yang SH *et al* (12%)¹⁷

In our study mean age of the women (24.17 ± 2.86 years) was lower than mean age of the women observed by Moon Sook Hwang (32.14 ± 4.11 years)¹⁹, and Martin A M *et al* (31.7 ± 5.0 years)²⁰. This may be due to practice of early marriage which is still prevalent in our state. Mean age of the women was significantly more in women with GDM than without GDM. ($p < 0.0000$). Our results were consistent with results of Kansu-Celik H *et al*². Mean BMI and Mean SCFT of the women in our study were lower than Mean BMI and SCFT observed by Yang SH *et al*,¹⁷ Martin A M *et al*²⁰ and De Souza *et al*²¹. There was significant difference in mean SCFT and BMI in women with GDM and without GDM and our results were in line with results observed by Kansu-Celik H *et al*², Yang SH *et al*¹⁷ and D'Ambrosi F *et al*²².

In present study, ROC curve analysis showed that pre-pregnancy BMI above 25 kg/m^2 (AUC=0.984) predicted GDM with a sensitivity of 100% and specificity of 93.4% with Youden index of 0.93. ROC curve analysis for ASCFT showed that ASCFT above 15.2 mm (AUC=0.970) predicted GDM with a sensitivity of 100% and specificity of 85.6 with Youden index of 0.86. Kansu-Celik H *et al*² in their study observed that BMI above 25.75 kg/m^2 predicted GDM with a sensitivity of 78.2%, a specificity of 40.9% and SAT (abdominal subcutaneous adipose tissue) thickness above 16.75 mm had a sensitivity of 71.7%, a specificity of 57.1%. Yang SH *et al*¹⁷ in their study observed that BMI above 21.8 kg/m^2 (AUC=0.71) predicted GDM with a sensitivity and specificity of 80.49% and 57.19%, respectively with a Youden index of 0.377 and ASCFT above 2.4 cm (AUC= 0.90) predicted GDM with sensitivity and specificity of 75.61% and 91.78%, respectively with a Youden index of 0.674.

The role of SAT in the development of GDM is not exactly clear. Some recent studies demonstrated that subcutaneous adiposity is associated with insulin resistance^{23,24}. A recent study revealed that increased biological activity in the SAT of pregnant women was associated with inflammation. The secretion of inflammatory agents, for example, leptin, adiponectin, and retinol-binding protein-4, was detected higher in subcutaneous tissue than in visceral adipocytes²⁵. In addition, it was shown that increased inflammation and cytokines produced by fat tissue induce insulin resistance that leads to the development of diabetes mellitus^{21,26}. In our study at a cut-off value of 15.2 mm for ASCFT, the risk of developing GDM was significantly high [odds ratio-117 (95% CI 14.9262-917.1130, $p < 0.0001$)]. Our results were consistent with results of Yang SH *et al*¹⁷, Kennedy NJ *et al*²⁷, Kosus *et al*²⁸. All of them in their respective studies observed increase in the risk of GDM with increase in SCFT. In a retrospective cohort study by Suresh *et al*²⁹, it was observed that the median SAT was 18.2 mm and for every 5 mm increase in SAT, the odds ratio for developing GDM was 1.40 (95% CI: 1.22–1.61, $p < 0.001$). Our results were in contrast with the results of De Souza *et al*²¹ and D'Ambrosi F *et al*²². They reported that visceral adipose thickness, but not subcutaneous adipose thickness, was significantly and independently associated with GDM. The difference in the thickness of subcutaneous fat in different studies shows that SAT thickness changes during pregnancy from women to women and it may be due to differences in socioeconomic status, physical activity, and diets between nationalities^{2,30}.

CONCLUSION

Ultrasonographic measurement of ASCFT is a reliable, quick and cost-effective method and we found that ultrasonographic ASCFT measurement at 16–18 weeks of pregnancy predicted GDM with 100% sensitivity and 91.78% specificity therefore measurement of ASCFT by ultrasonography may be helpful in predicting risk of GDM in pregnancy. During antenatal checkup, women with increased ASCFT can be counselled about the risk of developing GDM, diet modification and exercises so as to prevent GDM in later pregnancy.

Conflicts of interest: NIL

Source of Funding: Nil

References

1. American Diabetes Association. Gestational diabetes mellitus. *Diabetes Care*. 2004;27(Suppl 1):S88–90.
2. Kansu-Celik H, Karakaya BK, Tasci Y, Hancerliogullari N, Yaman S, Ozel S, Erkaya S. Relationship maternal subcutaneous adipose tissue thickness and development of gestational diabetes mellitus. *Interv Med Appl Sci*. 2018 Mar;10(1):13-18. doi: 10.1556/1646.10.2018.01. PMID: 30363336; PMCID: PMC6167636.
3. Hakkarainen H, Huopio H, Cederberg H, Pääkkönen M, Voutilainen R, Heinonen S: The risk of metabolic syndrome in women with previous GDM in a long-term follow-up. *Gynecol Endocrinol* 2016, 32, 920–925
4. de Koning L, Merchant AT, Pogue J, Anand SS: Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies. *Eur Heart J* 2007, 28, 850–856
5. Liu, J., Song, G., Meng, T. *et al*. Epicardial adipose tissue thickness as a potential predictor of gestational diabetes mellitus: a prospective cohort study. *BMC Cardiovasc Disord* **20**, 184 (2020). <https://doi.org/10.1186/s12872-020-01480-7>
6. Nguyen CL, Pham NM, Binns CW, Duong DV, Lee AH. Prevalence of Gestational Diabetes Mellitus in Eastern and Southeastern Asia: A Systematic Review and Meta-Analysis. *J Diabetes Res*. 2018;2018:10. Article ID 6536974
7. Raja MW, Baba TA, Hanga AJ, Bilquees S, Rasheed, Haq IU, *et al*. A study to estimate the prevalence of gestational diabetes mellitus in an urban block of Kashmir valley (North India) *Int J Med Sci Public Health*. 2014;3:191–5.
8. Gopalakrishnan V, Singh R, Pradeep Y, Kapoor D, Rani AK, Pradhan S, *et al*. Evaluation of the prevalence of gestational diabetes mellitus in North Indians using the International Association of Diabetes and Pregnancy Study groups (IADPSG) criteria. *J Postgrad Med*. 2015;61:155–8.
9. Wahi P, Dogra V, Jandial K, Bhagat R, Gupta R, Gupta S, *et al*. Prevalence of gestational diabetes mellitus (GDM) and its outcomes in Jammu region. *J Assoc Physicians India*. 2011;59(4):227–30.
10. Lauring JR, Kunselman AR, Pauli JM, Repke JT, Ural SH. Comparison of healthcare utilization and outcomes by gestational diabetes diagnostic criteria. *J Perinat Med*. 2018;46(4):401–9.

11. Corrado F, Pintaudi B. Diagnosis of gestational diabetes mellitus: Italian perspectives on risk factor-based Screening. In: Nutrition and diet in Maternal diabetes. Cham: Humana Press; 2018. p. 87–97
12. Huvinen E, Eriksson JG, Koivusalo SB, Grotenfelt N, Tiitinen A, StachLempinen B, *et al.* Heterogeneity of gestational diabetes (GDM) and longterm risk of diabetes and metabolic syndrome: findings from the RADIEL study follow-up. *Acta Diabetol.* 2018;55:493–501
13. Seshiah V, Balaji V, Balaji S, Sekar A, Sanjeevi CB, Green A, One step screening procedure for screening and diagnosis of gestational diabetes mellitus *J ObstetGynecol India* 2005; 55(6):525-29.
14. Kang HJ, Kwak HM, Kim YS, Park JS, Yoon G, Choi SJ, Oh SY, Kim JH, Roh CR. Obstetric and neonatal outcomes after treatment of gestational diabetes mellitus class A1 and class A2. *Korean J ObstetGynecol* 2010;53:681-6.
15. Choi HM. Perinatal outcomes associated with prepregnancy body mass index and weight gain during pregnancy. *Korean J ObstetGynecol* 2010;53:981-7.
16. Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. *Prenat Diagn.* 2011 Feb;31(2):135-41. doi: 10.1002/pd.2636. Epub 2010 Dec 28. PMID: 21268030.
17. Yang SH, Kim C, An HS, An H, Lee JS. Prediction of Gestational Diabetes Mellitus in Pregnant Korean Women Based on Abdominal Subcutaneous Fat Thickness as Measured by Ultrasonography. *Diabetes Metab J.* 2017 Dec;41(6):486-491. doi: 10.4093/dmj.2017.41.6.486. Epub 2017 Sep 22. PMID: 29199403; PMCID: PMC5741558.
18. IDF Diabetes Atlas. 6th ed. International Diabetes Federation, Belgium; 2013.
19. Hwang MS. Abdominal skin fat thickness over the gestational period in Korean pregnant women: a descriptive observational study [internet] *Korean Journal of Women Health Nursing.* Korean Society of Women Health Nursing. 2021, 27; 318-25
20. Martin AM, Berger H, Nisenbaum R, Lausman AY, MacGarvie S, Crerar C, Ray JG. Abdominal visceral adiposity in the first trimester predicts glucose intolerance in later pregnancy. *Diabetes Care.* 2009 Jul;32(7):1308-10. doi: 10.2337/dc09-0290. Epub 2009 Apr 23. PMID: 19389819; PMCID: PMC2699729.
21. De Souza LR, Berger H, Retnakaran R, Maguire JL, Nathens AB, Connelly PW, Ray JG. First-trimester maternal abdominal adiposity predicts dysglycemia and gestational diabetes mellitus in midpregnancy. *Diabetes Care* 2016;39:61-4
22. D'Ambrosi F, Rossi G, Soldavini CM, Di Maso M, Carbone IF, Cetera GE, Colosi E, Ferrazzi E. Ultrasound assessment of maternal adipose tissue during 1st trimester screening for aneuploidies and risk of developing gestational diabetes. *Acta ObstetGynecol Scand.* 2020 May;99(5):644-650. doi: 10.1111/aogs.13800. Epub 2020 Jan 16. PMID: 31898313
23. Goel K, Misra A, Vikram NK, Poddar P, Gupta N: Subcutaneous abdominal adipose tissue is associated with the metabolic syndrome in Asian Indians independent of intra-abdominal and total body fat. *Heart.*2010;96: 579–583
24. Tumurbaatar B, Poole AT, Olson G, Makhlof M, Sallam HS, Thukuntla S, Kankanala S, Ekhaese O, Gomez G, Chandalia M, Abate N: Adipose tissue insulin resistance in gestational diabetes. *Metab Syndr RelatDisord* 2017; 15, 86–92
25. Mazaki-Tovi S, Vaisbuch E, Tarca AL, Kusanovic JP, Than NG, Chaiworapongsa T, Dong Z, Hassan SS, Romero R: Characterization of visceral and subcutaneous adipose tissue transcriptome and biological pathways in pregnant and non-pregnant women: Evidence for pregnancy-related regional-specific differences in adipose tissue. *PLoS One* 10, 2015; e0143779
26. Baliutavičienė D, Buinauskienė JB, Petrenko V, Danytė E, Žalinkevičius R: Gestational diabetes, obesity, and metabolic syndrome diagnosed during pregnancy. *Metab Syndr RelatDisord* 2012; 10, 214–217
27. Kennedy NJ, Peek MJ, Quinton AE, Lanzarone V, Martin A, Benzie R, Nanan R: Maternal abdominal subcutaneous fat thickness as a predictor for adverse pregnancy outcome: A longitudinal cohort study. *BJOG* 2016; 123, 225–232
28. Köşüş N, Köşüş A, Turhan N: Relation between abdominal subcutaneous fat tissue thickness and inflammatory markers during pregnancy. *Arch Med Sci.* 2014; 10, 739–745
29. Suresh A, Liu A, Poulton A, Quinton A, Amer Z, Mongelli M, Martin A, Benzie R, Peek M, Nanan R: Comparison of maternal abdominal subcutaneous fat thickness and body mass index as markers for pregnancy outcomes: A stratified cohort study. *Aust N Z J Obstet Gynaecol* 2012; 52, 420–426
30. Widen EM, Gallagher D: Body composition changes in pregnancy: measurement, predictors and outcomes. *Eur J Clin Nutr* 2014;68, 643–652

How to cite this article:

Aditi Arora *et al* (2022) 'Predictive Analysis of Maternal Subcutaneous Fat Thickness For The Risk of Development of Gestational Diabetes Mellitus', *International Journal of Current Advanced Research*, 11(04), pp. 620-623. DOI: <http://dx.doi.org/10.24327/ijcar.2022.623.0138>
